 Narcotic Antagonists
"Narcotic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents inhibiting the effect of narcotics on the central nervous system.
| Descriptor ID |
D009292
|
| MeSH Number(s) |
D27.505.696.543 D27.505.696.663.850.512 D27.505.954.427.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Narcotic Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Narcotic Antagonists".
This graph shows the total number of publications written about "Narcotic Antagonists" by people in UAMS Profiles by year, and whether "Narcotic Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 1 | 2 | 3 | | 2023 | 0 | 1 | 1 | | 2022 | 0 | 3 | 3 | | 2021 | 1 | 2 | 3 | | 2020 | 2 | 1 | 3 | | 2019 | 2 | 3 | 5 | | 2018 | 3 | 1 | 4 | | 2017 | 1 | 0 | 1 | | 2016 | 2 | 1 | 3 | | 2015 | 0 | 3 | 3 | | 2014 | 1 | 1 | 2 | | 2013 | 4 | 4 | 8 | | 2012 | 4 | 1 | 5 | | 2011 | 3 | 3 | 6 | | 2010 | 2 | 0 | 2 | | 2009 | 1 | 1 | 2 | | 2008 | 5 | 0 | 5 | | 2007 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2005 | 6 | 2 | 8 | | 2004 | 4 | 2 | 6 | | 2003 | 2 | 1 | 3 | | 2002 | 1 | 3 | 4 | | 2001 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 1999 | 1 | 1 | 2 | | 1998 | 0 | 2 | 2 | | 1997 | 0 | 1 | 1 | | 1996 | 2 | 0 | 2 | | 1995 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Narcotic Antagonists" by people in Profiles over the past ten years.
-
Hiranita T, Flynn SM, Grisham AK, Mijares AE, Murphy EN, France CP. Gabapentinoids Increase the Potency of Fentanyl and Heroin and Decrease the Potency of Naloxone to Antagonize Fentanyl and Heroin in Rats Discriminating Fentanyl. J Pharmacol Exp Ther. 2024 Oct 18; 391(2):317-334.
-
Jones CM, Shoff C, Blanco C, Losby JL, Ling SM, Compton WM. Overdose, Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose. JAMA Intern Med. 2024 Aug 01; 184(8):954-962.
-
Hayes CJ, Martin BC, Hoggatt KJ, Cucciare MA, Hudson TJ, Gordon AJ. Average Daily Dose Trajectories for Episodes of Buprenorphine Treatment for Opioid Use Disorder. Subst Use Addctn J. 2024 Oct; 45(4):727-735.
-
Tackett WR, Yalakala J, Hambuchen MD. Co-administration of naloxone and dexmedetomidine to simultaneously reverse acute effects of fentanyl and methamphetamine in rats. Drug Alcohol Depend. 2024 Jun 01; 259:111301.
-
Riley E, Trotter S, Dayer L, Teigen A, Nagel C, Stickley K, LaBorde P, Richardson L, McFerguson R, Ward N, Anders M. Interprofessional Naloxone Student Training to Manage Suspected Opioid Overdose. Clin Nurse Spec. 2023 Jan-Feb 01; 37(1):26-35.
-
Costantino RC, Tilley LC, Gressler LE, Zarzabal LA, Vasquez CM, Peters S, Pakieser J, Highland KB, dosReis S. Naloxone Prescribing Associated With Reduced Emergency Department Visits in the Military Health System. Med Care. 2022 12 01; 60(12):901-909.
-
Griffith PS, Brown LM, Lensing SY, Nahata R, Padala PR, Snow L, Milholland K, Mullins M. Opioid Use Disorder: Treatment Outcomes in U.S. Veterans. J Addict Nurs. 2022 Oct-Dec 01; 33(4):322-325.
-
Hohmann LA, Fox BI, Garza KB, Wang CH, Correia C, Curran GM, Westrick SC. Impact of a Multicomponent Educational Intervention on Community Pharmacy-Based Naloxone Services Implementation: A Pragmatic Randomized Controlled Trial. Ann Pharmacother. 2023 06; 57(6):677-695.
-
Hawk K, Hoppe J, Ketcham E, LaPietra A, Moulin A, Nelson L, Schwarz E, Shahid S, Stader D, Wilson MP, D'Onofrio G. Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department. Ann Emerg Med. 2021 09; 78(3):434-442.
-
Coker JL, Ray-Griffith SL, McLeod C, Han X, Mancino M, Kearns GL, Stowe ZN. Clearance of buprenorphine during pregnancy and neonatal outcomes. Arch Womens Ment Health. 2021 12; 24(6):933-939.
-
Woody GE, Poole S, Yu E, Carroll J, Lynch KG. Extended release injectable naltrexone before vs. after release: A randomized trial of opioid addicted persons who are in prison. J Subst Abuse Treat. 2021 08; 127:108355.
-
Mitchell MM, Schwartz RP, Choo TH, Pavlicova M, O'Grady KE, Gryczynski J, Stitzer ML, Nunes EV, Rotrosen J. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis. Drug Alcohol Depend. 2021 02 01; 219:108422.
-
Acharya M, Chopra D, Hayes CJ, Teeter B, Martin BC. Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users. Value Health. 2020 04; 23(4):451-460.
-
Peterson LE, Morgan ZJ, Borders TF. Practice Predictors of Buprenorphine Prescribing by Family Physicians. J Am Board Fam Med. 2020 Jan-Feb; 33(1):118-123.
-
Bolin EH, Escalona-Vargas D, Daily JA, Siegel ER, Lowery CL, Coker J, Stowe ZN, Eswaran H. Magnetocardiographic identification of prolonged fetal corrected QT interval in women receiving treatment for opioid use disorder. J Obstet Gynaecol Res. 2019 Oct; 45(10):1989-1996.
-
Hiranita T, Leon F, Felix JS, Restrepo LF, Reeves ME, Pennington AE, Obeng S, Avery BA, McCurdy CR, McMahon LR, Wilkerson JL. The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats. Psychopharmacology (Berl). 2019 Sep; 236(9):2725-2734.
-
Derefinko KJ, Salgado Garc?a FI, Talley KM, Bursac Z, Johnson KC, Murphy JG, McDevitt-Murphy ME, Andrasik F, Sumrok DD. Adverse childhood experiences predict opioid relapse during treatment among rural adults. Addict Behav. 2019 09; 96:171-174.
-
Lake EP, Mitchell BG, Shorter DI, Kosten T, Domingo CB, Walder AM. Buprenorphine for the treatment of posttraumatic stress disorder. Am J Addict. 2019 02; 28(2):86-91.
-
Wen H, Borders TF, Cummings JR. Trends In Buprenorphine Prescribing By Physician Specialty. Health Aff (Millwood). 2019 01; 38(1):24-28.
-
Lovallo WR, Acheson A, Vincent AS, Sorocco KH, Cohoon AJ. Early life adversity diminishes the cortisol response to opioid blockade in women: Studies from the Family Health Patterns project. PLoS One. 2018; 13(10):e0205723.
-
Coker JL, Catlin D, Ray-Griffith S, Knight B, Stowe ZN. Buprenorphine medication-assisted treatment during pregnancy: An exploratory factor analysis associated with adherence. Drug Alcohol Depend. 2018 11 01; 192:146-149.
-
Yadlapalli JSK, Bommagani SB, Mahelona RD, Wan A, Gannon BM, Penthala NR, Dobretsov M, Crooks PA, Fantegrossi WE. Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-O-sulfate in rats: Drug discrimination and physical dependence. Pharmacol Res Perspect. 2018 07; 6(4):e00403.
-
Brinkley-Rubinstein L, Zaller N, Martino S, Cloud DH, McCauley E, Heise A, Seal D. Criminal justice continuum for opioid users at risk of overdose. Addict Behav. 2018 11; 86:104-110.
-
Wen H, Hockenberry JM, Borders TF, Druss BG. Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment. Med Care. 2017 04; 55(4):336-341.
-
Owens SM, Pollard GT, Howard JL, Fennell TR, Snyder RW, Carroll FI. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats. ACS Chem Neurosci. 2016 12 21; 7(12):1737-1745.
-
Tanda G, Mereu M, Hiranita T, Quarterman JC, Coggiano M, Katz JL. Lack of Specific Involvement of (+)-Naloxone and (+)-Naltrexone on the Reinforcing and Neurochemical Effects of Cocaine and Opioids. Neuropsychopharmacology. 2016 10; 41(11):2772-81.
-
Saucier CD, Zaller N, Macmadu A, Green TC. An Initial evaluation of law enforcement overdose training in Rhode Island. Drug Alcohol Depend. 2016 May 01; 162:211-8.
-
Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016; 35(1):22-35.
-
Lovallo WR, Enoch MA, Acheson A, Cohoon AJ, Sorocco KH, Hodgkinson CA, Vincent AS, Glahn DC, Goldman D. Cortisol Stress Response in Men and Women Modulated Differentially by the Mu-Opioid Receptor Gene Polymorphism OPRM1 A118G. Neuropsychopharmacology. 2015 Oct; 40(11):2546-54.
-
Northcutt AL, Hutchinson MR, Wang X, Baratta MV, Hiranita T, Cochran TA, Pomrenze MB, Galer EL, Kopajtic TA, Li CM, Amat J, Larson G, Cooper DC, Huang Y, O'Neill CE, Yin H, Zahniser NR, Katz JL, Rice KC, Maier SF, Bachtell RK, Watkins LR. DAT isn't all that: cocaine reward and reinforcement require Toll-like receptor 4 signaling. Mol Psychiatry. 2015 Dec; 20(12):1525-37.
-
Murphy BL, Ravichandran C, Babb SM, Cohen BM. Naltrexone in bipolar disorder with depression: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014 Dec; 34(6):749-51.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|